Abiopharma

🔍 Bruno Marc A (Executive)

Company: Aramark (ARMK)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 78,689 shares of Common Stock at $24.58 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 449,995.23 | transaction_form_type: 4
• Acquired 57,060 shares of Common Stock at $29.38 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 507,055.23 | transaction_form_type: 4
• Acquired 74,653 shares of Common Stock at $26.5 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 581,708.23 | transaction_form_type: 4
• Sold 139,768 shares of Common Stock at $60.35 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 441,940.23 | transaction_form_type: 4 | Footnotes: F1
• Sold 55,245 shares of Common Stock at $60.92 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 386,695.23 | transaction_form_type: 4 | Footnotes: F2
• Sold 15,389 shares of Common Stock at $61.42 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | shares_owned_after: 371,306.23 | transaction_form_type: 4 | Footnotes: F3
• Sold 78,689 shares of Stock Option (Right to Buy) at $24.58 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2026-11-18 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4
• Sold 57,060 shares of Stock Option (Right to Buy) at $29.38 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2027-11-16 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5
• Sold 74,653 shares of Stock Option (Right to Buy) at $26.5 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2028-11-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Shares withheld by Aramark (the "Issuer") to cover exercise price of options and tax withholding obligations.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.35 to $61.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.35 to $61.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: These options are fully vested and were scheduled to expire on November 18, 2026.
• F5: These options are fully vested and were scheduled to expire on November 16, 2027.
• F6: These options are fully vested and were scheduled to expire on November 15, 2028.